Profusa signs exclusive worldwide license with Mayo Clinic for oxygen monitoring and CLTI

Profusa, Inc.

Profusa granted exclusive worldwide license from Mayo for patent rights in continuous oxygen measurement and Critical Limb-Threatening Ischemia (CLTI).
Collaboration to support U.S. commercialization of Lumee wearable continuous tissue oxygen monitoring for critical limb ischemia.
Potential new indications include cardiovascular, renal, multi-organ, and orthopedic postoperative perfusion monitoring.
Profusa CEO notes over $100M invested in Lumee; Mayo retains financial interest for not-for-profit mission.
Financial terms include royalties on net sales, milestone payments, and share of sublicense income.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Profusa, Inc. entered into License Agreement with Mayo Foundation for Medical Education and Research (effective 2026-02-11).

Action: entry
Agreement: license
Counterparty: Mayo Foundation for Medical Education and Research
Effective: 2026-02-11

Exact text from the filing

On February 11, 2026, Profusa, Inc. (the “Company”) entered into a know-how license agreement (the “License Agreement”) with Mayo Foundation for Medical Education and Research (“Mayo”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Profusa, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-016496

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.